Robotic vs Laser Surgery for Enlarged Prostate

Overseen By Ruben Sauer, MD

Age: 18+

Sex: Male

Trial Phase: Academic

Sponsor: University of Illinois at Chicago

Disqualifiers: Cognitive impairment, Coagulopathy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 31

Duration: 1 day

116 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests two surgeries for treating an enlarged prostate, which can cause urination problems. One method uses a robot to assist in removing the prostate, while the other employs a laser (Laser Surgery). The researchers aim to determine which method is more effective and has fewer side effects. Men with an enlarged prostate who have not found relief from medications might be suitable candidates for this trial. As an unphased trial, it offers patients the chance to explore innovative surgical options that might yield better outcomes than current treatments.

Will I have to stop taking my current medications?

The trial protocol does not specify whether you need to stop taking your current medications. However, since the trial is for patients who have not had success with drug therapy, it's possible that you may need to stop those specific medications.

What prior data suggests that these surgical techniques are safe for treating BPH?

Research has shown that both single port robotic surgery and laser surgery for an enlarged prostate are generally safe and well-tolerated. Single port robotic surgery, a new and less invasive option, has shown promising results. Studies suggest it can effectively treat large non-cancerous prostate growths with fewer complications, often resulting in less pain and faster recovery compared to traditional surgery.

For laser surgery, research indicates it is both effective and safe for treating large prostates. Thulium laser enucleation, in particular, causes less damage to surrounding tissue. However, some patients may temporarily experience urinary incontinence (loss of bladder control) after the procedure, affecting about 15% of patients at one month, though it usually improves over time.

Both treatments have been well-studied and offer benefits with manageable risks. Discussing all possible side effects and recovery expectations with a healthcare provider is important before choosing a treatment. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about these treatments for enlarged prostate because they offer less invasive options compared to traditional surgery. Single Port Robotic Prostatectomy uses a single incision to remove the prostate, potentially reducing recovery time and minimizing scarring. Laser Enucleation of the Prostate uses precise laser technology to remove prostate tissue, which may lead to fewer complications like bleeding. Both of these methods aim to improve patient outcomes by offering effective alternatives with potentially quicker recovery and fewer side effects than standard surgical approaches.

What evidence suggests that this trial's treatments could be effective for BPH?

This trial will compare single-port robotic prostate surgery with laser enucleation for treating an enlarged prostate. Research has shown that both treatments are promising. Participants may receive single-port robotic surgery, which studies indicate is a less invasive option that effectively removes large prostate growths with potentially fewer risks and complications. This robotic method offers precision and may lead to quicker recovery times.

Alternatively, participants may receive thulium laser enucleation, which efficiently removes prostate tissue with less bleeding and faster symptom relief compared to traditional methods. It also allows for quicker recovery with less need for post-surgery care, such as using a catheter. Both treatments have demonstrated positive results, providing effective options for those with an enlarged prostate. ^{3 6 7 8 9}

Who Is on the Research Team?

Simone Crivellaro, MD

Principal Investigator

University of Illinois at Chicago, Department of Urology

Are You a Good Fit for This Trial?

Men with symptomatic Benign Prostatic Hyperplasia (BPH) not relieved by medication are eligible for this trial. It's not open to those who can't consent, prisoners, adults with cognitive impairments, or individuals with coagulopathy (a condition affecting blood clotting).

Inclusion Criteria

I have BPH symptoms that didn't improve with medication, so I need surgery.

Exclusion Criteria

I have a cognitive impairment.

I am unable to give consent for medical procedures.

Prisoners

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo either SP robotic simple prostatectomy or thulium laser enucleation of the prostate

1 day

1 visit (in-person)

Immediate Postoperative

Participants are monitored for perioperative parameters such as operative time, estimated blood loss, and hospital stay

Up to 30 days

Hospital stay (up to 30 days)

Follow-up

Participants are monitored for safety and effectiveness, including urinary flow rate and quality of life measures

7 months

Multiple visits (in-person and virtual)

What Are the Treatments Tested in This Trial?

Interventions

• Laser Surgery
• Single Port Robotic Surgery

Trial Overview

The trial is comparing two surgical approaches for BPH: a new robotic-assisted surgery using the da Vinci single-port platform and traditional thulium laser enucleation. Participants will be randomly assigned to one of these treatments.

How Is the Trial Designed?

Group I: Single Port Robotic Prostatectomy Active Control 1 Intervention

Removal of the prostate using single port robot

Group II: Laser Enucleation of the Prostate Active Control 1 Intervention

Enucleation of the prostate with laser surgery

Laser Surgery is already approved in United States, European Union for the following indications:

Approved in United States as Laser Surgery for:

• Benign Prostatic Hyperplasia (BPH)
• Bladder Outlet Obstruction (BOO)

Approved in European Union as Laser Surgery for:

• Benign Prostatic Hyperplasia (BPH)
• Bladder Outlet Obstruction (BOO)

Who Is Running the Clinical Trial?

University of Illinois at Chicago

Lead Sponsor

Trials

653

Recruited

1,574,000+

Published Research Related to This Trial

The novel 'All-in-One' technique for thulium laser enucleation of the prostate (ThuLEP) demonstrated significant improvements in key parameters for 47 patients with benign prostatic hyperplasia (BPH), including a mean operative time of 82.1 minutes and no major complications.

This technique resulted in a high PSA reduction ratio (0.81) and a low enucleation failure rate (4.3%), indicating its efficacy and effectiveness are comparable to existing methods, while potentially reducing operation time and bleeding.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A novel one lobe technique of thulium laser enucleation of the prostate: 'All-in-One' technique. Kim, YJ., Lee, YH., Kwon, JB., et al.[2019]

In a study of 102 men undergoing surgery for benign prostatic hyperplasia, both thulium laser enucleation of the prostate (ThuLEP) and single-port robot-assisted simple prostatectomy (SP RASP) showed similar improvements in International Prostate Symptom Scores (IPSS), indicating comparable efficacy in symptom relief.

SP RASP had a longer operative time but resulted in significantly lower rates of postoperative stress urinary incontinence compared to ThuLEP, suggesting that while both methods are effective, SP RASP may offer better continence outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Surgical treatment of benign prostatic hyperplasia: Thulium enucleation versus single-port transvesical robotic simple prostatectomy. Talamini, S., Lai, A., Palmer, C., et al.[2023]

Endoscopic enucleation of the prostate (EEP) techniques, particularly using thulium lasers, have gained popularity for treating benign prostatic hyperplasia (BPH) due to their reduced complications and shorter hospital stays compared to traditional methods like TURP.

Thulium laser techniques, including Thulium Laser Vapoenucleation and Thulium Laser Enucleation, offer effective alternatives to HoLEP and TURP, although there is less literature and fewer randomized controlled trials supporting their use.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Current evidence of ThuLEP for BPH: A review of literature. Bozzini, G., Berti, L., Maltagliati, M., et al.[2022]

In a study of 94 patients with large volume benign prostatic hyperplasia, both thulium vapoenucleation and holmium laser enucleation showed significant improvements in urinary flow and quality of life at 6 months post-surgery, with no significant differences between the two methods.

Both procedures were found to be safe, with low complication rates and no reoperations required within the 6-month follow-up period, indicating their efficacy in treating this condition.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Thulium vapoenucleation of the prostate versus holmium laser enucleation of the prostate for the treatment of large volume prostates: preliminary 6-month safety and efficacy results of a prospective randomized trial. Becker, B., Herrmann, TRW., Gross, AJ., et al.[2019]

In a study of 693 patients with prostate hyperplasia, both thulium (ThuLEP) and holmium (HoLEP) enucleation techniques showed significant improvements in urinary function after 6 months, establishing them as effective treatment options.

Thulium enucleation was notably quicker than holmium enucleation, with an average procedure time of 77.4 minutes compared to 97.0 minutes for HoLEP, while monopolar enucleation took the longest at 112.9 minutes, indicating a potential advantage in efficiency for the thulium method.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Comparative analysis of the effectiveness of various techniques of endoscopic prostate enucleation in a single center]. Enikeev, DV., Glybochko, PV., Alyaev, YG., et al.[2018]

In a study of 98 BPH patients, both Holmium and Thulium lasers were effective in relieving lower urinary tract symptoms (LUTS) after transurethral enucleation, showing similar improvements in urinary function three months post-surgery.

Thulium laser surgery had a shorter operation time and less blood loss compared to Holmium laser, indicating better hemostatic properties, although Holmium laser provided better anatomical clarity during the procedure.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Comparison of holmium and thulium laser in transurethral enucleation of the prostate]. Shao, Q., Zhang, FB., Shang, DH., et al.[2013]

In a study of 116 patients with large-volume benign prostatic hyperplasia (BPH), both holmium laser enucleation of the prostate (HoLEP) and thulium laser enucleation of the prostate (ThuLEP) significantly improved lower urinary tract symptoms after 18 months, demonstrating high efficacy and safety for both methods.

ThuLEP was found to have shorter operative and enucleation times compared to HoLEP, making it a more efficient option, although both techniques showed similar outcomes in terms of symptom relief and quality of life.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Holmium laser enucleation of the prostate versus thulium laser enucleation of the prostate for the treatment of large-volume prostates > 80 ml: 18-month follow-up results. Zhang, J., Ou, Z., Zhang, X., et al.[2021]

Thulium laser enucleation of the prostate (ThuLEP) is associated with less blood loss and shorter hospital stays compared to Holmium laser enucleation of the prostate (HoLEP), based on a systematic review of 8 studies involving 2125 patients.

Patients undergoing ThuLEP showed a faster improvement in symptoms, as indicated by a significant reduction in the International Prostate Symptom Score (IPSS) at the 3-month follow-up, suggesting better clinical efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparison of enucleation between thulium laser and holmium laser for benign prostatic hyperplasia: A systematic review and meta-analysis. Meng, C., Peng, L., Li, J., et al.[2022]

Both Holmium laser enucleation of the prostate (HoLEP) and Thulium laser enucleation of the prostate (ThuLEP) are safe and effective surgical options for treating benign prostatic hyperplasia (BPH) in patients with prostate volumes greater than 100 ml, based on a study of 225 patients.

ThuLEP demonstrated advantages over HoLEP in terms of total operation time, laser efficiency, enucleation time, and enucleation efficiency, indicating it may be a more efficient option for larger prostates.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Laser enucleation for prostates larger than 100 mL: Comparison of HoLEP and ThuLEP. Kaya, E., Yılmaz, S., Açıkgöz, O., et al.[2021]

Thulium vapoenucleation of the prostate (ThuVEP) and holmium laser enucleation of the prostate (HoLEP) are both safe and effective treatments for benign prostatic obstruction, with similar outcomes in terms of urinary flow improvement and low complication rates among 94 patients studied.

However, ThuVEP showed a significantly lower rate of acute postoperative urinary retention compared to HoLEP (2.1% vs. 15.2%), suggesting it may be a preferable option for reducing this specific complication.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A prospective, randomized trial comparing thulium vapoenucleation with holmium laser enucleation of the prostate for the treatment of symptomatic benign prostatic obstruction: perioperative safety and efficacy. Netsch, C., Becker, B., Tiburtius, C., et al.[2022]

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC11055731/

A prospective analysis of thulium laser enucleation in ...

The primary outcome of the study was the enucleation efficiency, determined by the ratio of the resected weight of the prostate to the ...

2.

sciencedirect.com

sciencedirect.com/science/article/pii/S1015958421004632

Comparison of enucleation between thulium laser and ...

Our study demonstrates that ThuLEP, compared with HoLEP, has better security, faster improvement of symptoms.

3.

bmcurol.biomedcentral.com

bmcurol.biomedcentral.com/articles/10.1186/s12894-024-01517-5

The safety and efficacy of five surgical treatments in prostate ...

The aim of our study was to investigate the comparative outcomes of five different energy types on surgical efficacy and postoperative recovery

4.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC11059979/

A Prospective, Randomized Study Comparing the Outcome ...

The ThuLEP outperforms TURP in terms of blood loss, significantly less need for postoperative catheter traction, bladder irrigations, early catheter removal, ...

5.

hopkinsmedicine.org

hopkinsmedicine.org/health/conditions-and-diseases/benign-prostatic-hyperplasia-bph/prostate-holmium-laser-enucleation-holep

HoLEP Procedure: Holmium Laser Enucleation of the ...

In terms of effectiveness, practitioners report that holmium laser enucleation of the prostate has results comparable to those of simple prostatectomy but does ...

6.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/37731152/

Efficacy and safety of transurethral thulium laser ...

(HoLEP) and (RASP) are both effective and safe procedures for treating large-volume benign prostatic hyperplasia.

7.

sciencedirect.com

sciencedirect.com/science/article/pii/S2405456925000926

Lasers for Benign Prostatic Obstruction: And the Winner Is …

One of the main drawbacks of laser enucleation is postoperative urinary incontinence, which affects up to 15% of patients at 1 mo, and decreases ...

8.

auajournals.org

auajournals.org/doi/10.1097/JU.0000000000004297

Comparative Analysis of Holmium Laser Enucleation of the ...

HoLEP and RASP are effective for managing BPH. HoLEP shows advantages in recovery metrics and lower blood transfusion rates, while RASP benefits from ease of ...

9.

journals.lww.com

journals.lww.com/ursc/fulltext/2023/34040/a_comparative_study_of_the_efficacy_of_thulium.5.aspx

A Comparative Study of the Efficacy of Thulium Fiber Laser...

Thulium fiber laser enucleation of the prostate (ThuFLEP) reduces the thermal damage zone by fourfold (100 μm) and reduces the risk of scarring. 11 However, ...